''Baxter’s heritage of innovation has had a far-reaching impact on patient care,'' adds Parkinson. ''Innovation is the lifeblood of growth in today’s competitive marketplace, and our R&D investment has risen steadily to reflect this reality.''
A webcast of Baxter’s 2012 Investor Conference can be accessed live from a link on the company’s website at www.baxter.com beginning at 9:00 a.m. CDT on October 9, 2012. A replay of Baxter’s 2012 Investor Conference and accompanying presentation materials can be accessed from a link on the company’s website at www.baxter.com beginning October 10. Please visit Baxter’s website for more information regarding this and future investor events and webcasts.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
This release includes forward-looking statements concerning Baxter’s long-range plan, R&D pipeline, business development and other growth strategies, and capital allocation philosophy. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance risks for new and existing products; future actions of regulatory bodies and other governmental authorities, including the FDA and foreign counterparts; product quality or patient
safety concerns; U.S. healthcare reform and other austerity measures; reimbursement and rebate policies of government agencies and private payers; product development risks; accurate identification of business development and growth opportunities; timely submission and approval of regulatory filings; inventory reductions or fluctuations in buying patterns; the impact of geographic and product mix on the company's sales; the impact of competitive products and pricing, drug reimportation and disruptive technologies; the availability of acceptable raw materials and component supply; fluctuations of supply and demand and the pricing of plasma-based therapies; the ability to enforce company patents; patents of third parties preventing or restricting the company’s manufacture, sale or use of affected products or technology; realization of benefits from joint product development and commercialization arrangements; the impact of global economic conditions on Baxter and its customers, including foreign governments; foreign currency fluctuations and other risks identified in the company's most recent filing on Form 10-K and other SEC filings, all of which are available on the company's website. The company does not undertake to update its forward-looking statements. Financial schedules are available on the company’s website.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV